Rare disease families find roadmap to drug development at bootcamps

Developing a new drug can cost a billion dollars and take more than a decade. That makes investing in new treatments in the rare disease space — where patient populations are small, and the chance of earning a return on that investment even smaller — a risky bet for big pharmaceutical companies. That's a big reason why 95% of the more than 10,000 rare diseases that exist do not have an FDA-approved treatment. …